• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by GoodRx Holdings Inc.

    6/11/24 7:01:15 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email
    SC 13D/A 1 gdrx-trevorbezdekschedule1.htm SC 13D/A GDRX - Trevor Bezdek Schedule 13D (Amendment No. 2)
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D/A
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    GoodRx Holdings, Inc.
    (Name of Issuer)
    Class A Common Stock
    (Title of Class of Securities)
    38246G108
    (CUSIP Number)
    Trevor Bezdek
    c/o GoodRx Holdings, Inc.
    2701 Olympic Boulevard
    Santa Monica, CA 90404
    (855) 268-2822
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
    June 7, 2024
    (Date of Event Which Requires Filing of This Statement)
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject
    of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the
    following box. [ ]
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including
    all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.
    _____________
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with
    respect to the subject class of securities, and for any subsequent amendment containing information which would
    alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose
    of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of
    the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    1
    Names of Reporting Persons
    Trevor Bezdek
    2
    Check the Appropriate Box if a Member of a Group                                    (a) [ ]
                                                                                                                (b) [ ]
    3
    SEC Use Only
    4
    Source of Funds (See Instructions)
    OO
    5
    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ]
    6
    Citizenship or Place of Organization
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON
    WITH
    7
    Sole Voting Power
    2,632,721
    8
    Shared Voting Power
    2,632,721
    9
    Sole Dispositive Power
    2,632,721
    10
    Shared Dispositive Power
    2,632,721
    11
    Aggregate Amount Beneficially Owned by Each Reporting Person
    5,265,442
    12
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ]
    13
    Percent of Class Represented by Amount in Row (11)
    5.6%
    14
    Type of Reporting Person
    IN
    CUSIP No. 38246G108
    13D/A
    Page 1 of 6 pages
    EXPLANATORY NOTE
    This Amendment No. 2 to Schedule 13D (this “Amendment No. 2”) amends and
    supplements the statement on Schedule 13D filed with the Securities and Exchange Commission
    on August 31, 2023 (as amended to date, the “Schedule 13D”) relating to the shares of Class A
    Common Stock, par value $0.0001 per share (the “Class A Common Stock”), of GoodRx
    Holdings, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used but not defined
    herein shall have the meaning ascribed thereto in the Schedule 13D.
    Item 4.Purpose of Transaction.
    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:
    Gift Transactions
    On June 7, 2024, the Reporting Person gifted 2,632,721 shares of Class A Common
    Stock to the Reporting Person’s spouse.
    On June 10, 2024, the Reporting Person gifted 2,632,721 shares of Class A Common
    Stock to a grantor retained annuity trust (the “TB 2024 GRAT”) of which the Reporting Person
    is the sole trustee and annuitant. Also on June 10, 2024, the Reporting Person’s spouse gifted
    2,632,721 shares of Class A Common Stock to a grantor retained annuity trust (the “JB 2024
    GRAT”), of which the Reporting Person’s spouse is the sole trustee and annuitant.
    As a result of the foregoing transactions, the Reporting Person no longer has voting or
    dispositive power over the Class A Common Stock held by the JB 2024 GRAT. The Reporting
    Person does not exercise voting or dispositive power over the Class A Common Stock held of
    record by the JB 2024 GRAT. The inclusion in this Amendment No. 2 of the Class A Common
    Stock held of record by the JB 2024 GRAT and disclosure related thereto is not an admission or
    acknowledgement that the Reporting Person beneficially owns such Class A Common Stock.
    The Reporting Person disclaims beneficial ownership of the Class A Common Stock held by the
    JB 2024 GRAT.
    Rule 10b5-1 Trading Plans
    On June 7, 2024, pursuant to the Board’s prior approval in accordance with the terms of
    the Reporting Person’s Second Amended and Restated Employment Agreement, the Reporting
    Person terminated the Trading Plan and entered into a modified Rule 10b5-1 Plan (the “TB 2024
    GRAT Trading Plan”), pursuant to which the Reporting Person and the TB 2024 GRAT may
    make periodic sales of up to 2,632,721 shares of Class A Common Stock plus an undeterminable
    number of Class A Common Stock related to restricted stock units that have not yet vested. The
    amount and timing of sales, if any, pursuant to the TB 2024 GRAT Trading Plan may vary and
    CUSIP No. 38246G108
    13D/A
    Page 2 of 6 pages
    will be determined based on the terms of the TB 2024 GRAT Trading Plan, market conditions,
    share price and other factors.
    Also on June 7, 2024 and further pursuant to the Board’s prior approval in accordance
    with the terms of the Reporting Person’s Second Amended and Restated Employment
    Agreement, the Reporting Person’s spouse entered into a new Rule 10b5-1 Plan (the “JB 2024
    GRAT Trading Plan”), pursuant to which the JB 2024 GRAT may make periodic sales of up to
    2,632,721 shares of Class A Common Stock. The amount and timing of sales, if any, pursuant to
    the JB 2024 GRAT Trading Plan may vary and will be determined based on the terms of the JB
    2024 GRAT Trading Plan, market conditions, share price and other factors.
    The foregoing descriptions of the TB 2024 GRAT Trading Plan and the JB 2024 GRAT
    Trading Plan do not purport to be complete and are qualified in their entirety by the full text of
    such trading plans. A copy of each of the TB 2024 GRAT Trading Plan and the JB 2024 GRAT
    Trading Plan is filed as an exhibit to this Schedule 13D, and incorporated herein by reference.
    Item 5.Interest in Securities of the Issuer.
    Item 5 of the Schedule 13D is hereby amended and restated as follows:
    (a) – (b)
    •Amount beneficially owned: 5,265,442†
    •Percent of Class: 5.6%†
    •Number of shares the Reporting Person has:
    oSole power to vote or direct the vote: 2,632,721
    oShared power to vote: 2,632,721†
    oSole power to dispose or direct the disposition of: 2,632,721
    oShared power to dispose or direct the disposition of: 2,632,721†
    The share amount reported herein consists of (i) 2,632,721 shares of Class A Common
    Stock held by the TB 2024 GRAT and (ii) 2,632,721 shares of Class A Common Stock held by
    the JB 2024 GRAT.†
    The above percentage is based on 94,335,792 shares of Class A Common Stock
    outstanding as of April 30, 2024, as disclosed in the Quarterly Report of the Issuer on Form 10-Q
    filed with the Securities and Exchange Commission on May 9, 2024.
    CUSIP No. 38246G108
    13D/A
    Page 3 of 6 pages
    † The Reporting Person does not exercise voting or dispositive power over the Class A Common
    Stock held of record by the JB 2024 GRAT. The inclusion in this Amendment No. 2 of the Class
    A Common Stock held of record by the JB 2024 GRAT and disclosure related thereto is not an
    admission or acknowledgement that the Reporting Person beneficially owns such Class A
    Common Stock. The Reporting Person disclaims beneficial ownership of the Class A Common
    Stock held by the JB 2024 GRAT.
    (c)On June 1, 2024, the Reporting Person acquired 126,552 shares of Class A Common
    Stock as a result of the vesting of RSUs, after the Issuer withheld 130,042 shares of Class
    A Common Stock underlying Class B Common Stock from the Reporting Person to
    satisfy tax withholding obligations. Except as described in this Amendment No. 2, in the
    last 60 days, the Reporting Person has not effected any transactions with respect to the
    Class A Common Stock.
    (d)None.
    (e)Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to
    Securities of the Issuer.
    Item 6 of the Schedule 13D is hereby amended and supplemented as follows:
    Item 4 above summarizes certain provisions of the TB 2024 GRAT Trading Plan and the
    JB 2024 GRAT Trading Plan and is incorporated herein by reference. A copy of each of the TB
    2024 GRAT Trading Plan and the JB 2024 GRAT Trading Plan is attached as an exhibit to this
    Schedule 13D, and incorporated herein by reference.
    Item 7.Materials to be Filed as Exhibits.
    Item 7 of the Schedule 13D is hereby amended and supplemented as follows:
    Exhibit
    Number
    Description
    5
    TB 2024 GRAT Trading Plan.
    7
    JB 2024 GRAT Trading Plan.
    CUSIP No. 38246G108
    13D/A
    Page 4 of 6 pages
    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the
    information set forth in this statement is true, complete and correct.
    Date:  June 11, 2024
    By:
    /s/ Trevor Bezdek
    Name:
    Trevor Bezdek
    CUSIP No. 38246G108
    13D/A
    Page 5 of 6 pages
    Get the next $GDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/25/2024$7.50 → $10.00Equal Weight → Overweight
    Wells Fargo
    3/1/2024$7.00 → $10.00Neutral → Overweight
    JP Morgan
    2/26/2024$8.00Outperform
    Leerink Partners
    More analyst ratings

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/14/24 12:29:56 PM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/13/24 4:30:24 PM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/12/24 4:02:41 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Nabiey Romin converted options into 4,804 shares and covered exercise/tax liability with 1,719 shares, increasing direct ownership by 3% to 118,091 units (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      5/15/25 5:46:56 PM ET
      $GDRX
      EDP Services
      Technology
    • Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 4,531 shares, increasing direct ownership by 8% to 115,006 units (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      5/8/25 6:16:12 PM ET
      $GDRX
      EDP Services
      Technology
    • Director Idea Men, Llc converted options into 7,000,000 shares and returned $29,400,000 worth of shares to the company (7,000,000 units at $4.20) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      3/21/25 4:23:24 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on GoodRx with a new price target

      Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00

      12/4/24 7:38:07 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx upgraded by Raymond James with a new price target

      Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00

      8/9/24 7:30:17 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded GoodRx from Sector Perform to Outperform and set a new price target of $10.00 from $8.00 previously

      5/23/24 7:39:11 AM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.

      SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      5/15/25 10:57:58 AM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.

      SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      5/14/25 4:04:49 PM ET
      $GDRX
      EDP Services
      Technology
    • SEC Form 10-Q filed by GoodRx Holdings Inc.

      10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

      5/7/25 4:50:11 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      12/4/23 4:35:10 PM ET
      $GDRX
      EDP Services
      Technology
    • Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      11/30/23 4:41:35 PM ET
      $GDRX
      EDP Services
      Technology
    • Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      11/17/23 7:08:30 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GoodRx to Launch Direct Contracting for Independent Community Pharmacies

      GoodRx is hosting a webinar on June 3 and 4 to discuss how the company is supporting direct contracting with GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced that it will launch a new offering for independent community pharmacies - GoodRx Community Link - in June 2025. GoodRx Community Link will enable locally owned and operated pharmacies to directly contract with GoodRx on pricing and manage participation in the company's Integrated Savings Programs (ISP). Direct contracts leverage cost-plus models to provide independent pharmacies with more direct control over pricing and favorable margins. GoodRx is committed to helping independent

      5/22/25 9:00:00 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Reports First Quarter 2025 Results

      First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

      5/7/25 4:13:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

      GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

      4/9/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

      Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

      3/17/25 9:00:00 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer

      Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role. Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthca

      2/5/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology
    • WM Technology, Inc. Names Sarah Griffis Chief Technology Officer

      WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Sarah Griffis as the Company's new Chief Technology Officer, effective January 6, 2025. "I am thrilled to welcome Sarah as our new CTO. She has great experience not just building and leading engineering and tech teams, but also operating in regulated industries like ours," said Doug Francis, Chief Executive Officer at Weedmaps. "I look forward to partnering with her and the rest of our tech org to continue delivering innovative and best-in-class technology solutions to our customers." Prior to joining W

      1/6/25 9:00:00 AM ET
      $GDRX
      $MAPS
      EDP Services
      Technology
      Computer Software: Prepackaged Software

    $GDRX
    Financials

    Live finance-specific insights

    See more
    • GoodRx Reports First Quarter 2025 Results

      First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

      5/7/25 4:13:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

      GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

      4/9/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Reports Fourth Quarter and Full Year 2024 Results

      Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of $44.7 million Exited the quarter with over 7 million consumers of pr

      2/27/25 6:05:00 AM ET
      $GDRX
      EDP Services
      Technology